^
    Back
    Association details:
    Biomarker:EGFR expression
    Cancer:Squamous Cell Carcinoma of Head and Neck
    Drug:Erbitux (cetuximab) (EGFR inhibitor) +
    CYNK-101 (NK cell stimulant)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    SITC 2021
    Title:

    159 Developing placental CD34+-derived natural killer cells with high affinity cleavage resistant CD16 (CYNK-101) and Cetuximab for enhanced therapy of EGFR+ non-small cell lung and head and neck cancers

    Published date:
    11/09/2021
    Excerpt:
    Our results demonstrate that CYNK-101 have enhanced Cetuximab-mediated ADCC activity against EGFR+ NSCLC and HNSCC tumor cell lines.
    DOI:
    http://dx.doi.org/10.1136/jitc-2021-SITC2021.159